JP2005507861A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005507861A5 JP2005507861A5 JP2003516456A JP2003516456A JP2005507861A5 JP 2005507861 A5 JP2005507861 A5 JP 2005507861A5 JP 2003516456 A JP2003516456 A JP 2003516456A JP 2003516456 A JP2003516456 A JP 2003516456A JP 2005507861 A5 JP2005507861 A5 JP 2005507861A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- lapachone
- analog
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QZPQTZZNNJUOLS-UHFFFAOYSA-N beta-lapachone Chemical compound C12=CC=CC=C2C(=O)C(=O)C2=C1OC(C)(C)CC2 QZPQTZZNNJUOLS-UHFFFAOYSA-N 0.000 claims 92
- 239000008194 pharmaceutical composition Substances 0.000 claims 87
- 239000000203 mixture Substances 0.000 claims 40
- 238000009472 formulation Methods 0.000 claims 26
- 239000002246 antineoplastic agent Substances 0.000 claims 25
- 206010028980 Neoplasm Diseases 0.000 claims 24
- 230000003381 solubilizing effect Effects 0.000 claims 22
- 201000011510 cancer Diseases 0.000 claims 20
- 239000000839 emulsion Substances 0.000 claims 20
- 239000003937 drug carrier Substances 0.000 claims 19
- 239000007864 aqueous solution Substances 0.000 claims 13
- 239000002960 lipid emulsion Substances 0.000 claims 11
- 239000003981 vehicle Substances 0.000 claims 10
- 238000007911 parenteral administration Methods 0.000 claims 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 8
- 230000000699 topical effect Effects 0.000 claims 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 6
- 229920000642 polymer Polymers 0.000 claims 6
- 229920000858 Cyclodextrin Polymers 0.000 claims 5
- 239000000243 solution Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical group C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 3
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 239000001116 FEMA 4028 Substances 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 229920000954 Polyglycolide Polymers 0.000 claims 2
- 229920003078 Povidone K 12 Polymers 0.000 claims 2
- 229920003079 Povidone K 17 Polymers 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 2
- 229960004853 betadex Drugs 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 208000019420 lymphoid neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 229960000502 poloxamer Drugs 0.000 claims 2
- 229920001983 poloxamer Polymers 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 239000008389 polyethoxylated castor oil Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 239000004633 polyglycolic acid Substances 0.000 claims 2
- 239000004626 polylactic acid Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 239000008279 sol Substances 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 239000004375 Dextrin Substances 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 229930182556 Polyacetal Natural products 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229920000469 amphiphilic block copolymer Polymers 0.000 claims 1
- 229920006037 cross link polymer Polymers 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- IAODRFIZLKITMK-UHFFFAOYSA-N furan-2,3-dione Chemical compound O=C1OC=CC1=O IAODRFIZLKITMK-UHFFFAOYSA-N 0.000 claims 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 229940028435 intralipid Drugs 0.000 claims 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 229920002721 polycyanoacrylate Polymers 0.000 claims 1
- -1 polyethylene Polymers 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 229920000656 polylysine Polymers 0.000 claims 1
- 229920006324 polyoxymethylene Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30893501P | 2001-07-31 | 2001-07-31 | |
| US09/975,776 US6962944B2 (en) | 2001-07-31 | 2001-10-10 | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| PCT/US2002/024262 WO2003011224A2 (en) | 2001-07-31 | 2002-07-31 | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005507861A JP2005507861A (ja) | 2005-03-24 |
| JP2005507861A5 true JP2005507861A5 (enExample) | 2006-01-12 |
Family
ID=26976533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003516456A Pending JP2005507861A (ja) | 2001-07-31 | 2002-07-31 | β−ラパコン、あるいはその誘導体またはアナログを含む薬学的組成物、およびその使用法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6962944B2 (enExample) |
| EP (1) | EP1420777A4 (enExample) |
| JP (1) | JP2005507861A (enExample) |
| KR (1) | KR100734341B1 (enExample) |
| CN (1) | CN1561209A (enExample) |
| AU (1) | AU2002313713B2 (enExample) |
| BR (1) | BR0211613A (enExample) |
| CA (1) | CA2455567A1 (enExample) |
| EA (1) | EA007075B1 (enExample) |
| IL (2) | IL160108A0 (enExample) |
| MX (1) | MXPA04000994A (enExample) |
| NZ (1) | NZ531335A (enExample) |
| WO (1) | WO2003011224A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050192360A1 (en) * | 1999-04-14 | 2005-09-01 | Li Chiang J. | Method of treatment of pancreatic cancer |
| US20050197405A1 (en) * | 2000-11-07 | 2005-09-08 | Li Chiang J. | Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent |
| EP1435908A4 (en) * | 2001-09-13 | 2006-03-15 | Korea Inst Sci & Tech | Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof |
| US6890950B2 (en) * | 2002-04-23 | 2005-05-10 | Case Western Reserve University | Lapachone delivery systems, compositions and uses related thereto |
| CA2492772A1 (en) * | 2002-07-17 | 2004-01-22 | Chiang J. Li | Activated checkpoint therapy and methods of use thereof |
| AU2003293333A1 (en) * | 2002-12-02 | 2004-06-23 | Arqule, Inc. | Method of treating cancers |
| JP2007512378A (ja) * | 2003-11-26 | 2007-05-17 | アークル インコーポレイテッド | 放射線障害から保護するためのβ−ラパコンの使用 |
| EP1722777A2 (en) * | 2004-02-20 | 2006-11-22 | Arqule, Inc. | Use of beta-lapachone for the treatment of pancreatic cancer |
| CA2555941A1 (en) * | 2004-02-20 | 2005-09-09 | Arqule, Inc. | Use of beta-lapachone for treatment of colon cancer |
| EP1729760A2 (en) * | 2004-02-20 | 2006-12-13 | Arqule, Inc. | Use of beta-lapachone for the treatment of lung cancer |
| US20050187288A1 (en) * | 2004-02-20 | 2005-08-25 | Chiang Li | Beta-lapachone and methods of treating cancer |
| US20050192247A1 (en) * | 2004-02-23 | 2005-09-01 | Li Chiang J. | Method of treating cancers |
| US20050256097A1 (en) * | 2004-05-11 | 2005-11-17 | Kosan Biosciences, Inc. | Pharmaceutical solution formulations containing 17-AAG |
| CA2583700A1 (en) * | 2004-08-11 | 2006-02-23 | Arqule, Inc. | Quinone prodrug compositions and methods of use |
| US8614228B2 (en) * | 2004-08-11 | 2013-12-24 | Arqule, Inc. | Quinone prodrug compositions and methods of use |
| ITMI20041763A1 (it) * | 2004-09-16 | 2004-12-16 | Altergon Sa | Nuove formulazioni iniettabili contenenti progesterone |
| BRPI0615265A8 (pt) | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
| TW200824692A (en) * | 2006-08-21 | 2008-06-16 | Arqule Inc | Novel lapachone compounds and methods of use thereof |
| US7790765B2 (en) * | 2007-04-30 | 2010-09-07 | Arqule, Inc. | Hydroxy sulfonate of quinone compounds and their uses |
| CN101801937A (zh) | 2007-06-22 | 2010-08-11 | 艾科尔公司 | 喹唑啉酮化合物及其使用方法 |
| EP2193140B1 (en) | 2007-08-27 | 2016-11-02 | 1Globe Health Institute LLC | Compositions of asymmetric interfering rna and uses thereof |
| JP4792128B2 (ja) | 2007-10-12 | 2011-10-12 | アークル インコーポレイテッド | 癌に対するｈｓｐ９０阻害剤としての５−（２−ヒドロキシフェニル）テトラゾール |
| US8067459B2 (en) * | 2007-10-16 | 2011-11-29 | Arqule, Inc. | Lapachone compounds and methods of use thereof |
| KR101405823B1 (ko) | 2007-12-24 | 2014-06-12 | 주식회사 케이티앤지생명과학 | 녹내장의 치료 및 예방을 위한 약제 조성물 |
| KR20090071829A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | 신장질환의 치료 및 예방을 위한 약제 조성물 |
| KR20090073381A (ko) * | 2007-12-31 | 2009-07-03 | 주식회사 머젠스 | 심장질환의 치료 및 예방을 위한 약제 조성물 |
| KR101528265B1 (ko) * | 2010-04-16 | 2015-06-11 | 코웨이 주식회사 | 베타-라파콘을 유효성분으로 포함하는 주름개선용 화장료 조성물 |
| CN103429235A (zh) * | 2010-12-15 | 2013-12-04 | 赖鸿政 | 用于治疗癌症的化合物及其应用 |
| KR101583755B1 (ko) | 2012-10-29 | 2016-01-19 | 코웨이 주식회사 | 베타-라파콘을 유효성분으로 포함하는 신경계 질환 예방 및 치료용 조성물 |
| RU2530886C1 (ru) * | 2013-06-24 | 2014-10-20 | Государственное бюджетное учреждение "Уфимский научно-исследовательский институт глазных болезней Академии наук Республики Башкортостан" | Водорастворимый комплекс включения бета-циклодекстрин-гистохром, обладающий пролонгированным антиоксидантным действием |
| JP7042529B2 (ja) * | 2018-01-18 | 2022-03-28 | ナディアンバイオ・リミテッド | 脱毛の予防または軽減のための、有効成分としてダンニオンを含む組成物 |
| CN112076157B (zh) * | 2019-06-14 | 2022-04-26 | 首都医科大学 | 拉帕醇纳米脂质体制剂及其制备方法和应用 |
| TWI832069B (zh) * | 2020-07-10 | 2024-02-11 | 南韓商娜迪安生物公司 | 用於預防或治療癌症且含有萘醌系化合物及免疫檢查點抑制劑作為活性成分的藥學組成物 |
| KR20240014533A (ko) | 2021-05-29 | 2024-02-01 | 1글로브 헬스 인스티튜트 엘엘씨 | 신규한 유전자 침묵 기술로서의 짧은 듀플렉스 dna 및 이의 용도 |
| CA3221935A1 (en) | 2021-05-29 | 2022-12-08 | 1Globe Health Institute Llc | Asymmetric short duplex dna as a novel gene silencing technology and use thereof |
| KR20240096905A (ko) * | 2021-12-15 | 2024-06-26 | 신라젠(주) | 변형된 베타-사이클로덱스트린을 포함하는 약제학적 조성물 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2827452A (en) | 1955-05-31 | 1958-03-18 | Univ Minnesota | Stabilization of materials |
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
| HU184066B (en) | 1979-12-28 | 1984-06-28 | Chinoin Gyogyszer Es Vegyeszet | Plant growth regulating substance and process for preparing such compound |
| HU181703B (en) | 1980-05-09 | 1983-11-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents |
| US4371673A (en) | 1980-07-21 | 1983-02-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble forms of retinoids |
| AU558787B2 (en) | 1981-01-23 | 1987-02-12 | Wellcome Foundation Limited, The | Inclusion complexes of cyclodextrins and cardiac clycosides |
| JPS57126802A (en) | 1981-01-30 | 1982-08-06 | Mitsubishi Petrochem Co Ltd | Benzophenone-3,3'-disulfonate-capped compound of beta-cyclodextrin |
| JPS57200361A (en) | 1981-06-03 | 1982-12-08 | Sumitomo Chem Co Ltd | "indomethacin(r)" pharmaceutical with low irritant action |
| US4383992A (en) | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
| JPS58144376A (ja) | 1982-02-23 | 1983-08-27 | Sumitomo Chem Co Ltd | ベンゾジアゼピン誘導体−シクロデキストリン包接化合物 |
| HU190818B (en) | 1982-11-09 | 1986-11-28 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu | Process for producing complexes of piperonyl-butoxide-cyclodextrin |
| HU190584B (en) | 1983-03-11 | 1986-09-29 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara,Rt,Hu | Process for the production of heptakis/2,6-di-o-methyl-beta-cyclodextrin |
| DE3400488A1 (de) | 1983-03-16 | 1984-09-20 | Kraftwerk Union AG, 4330 Mülheim | Elektrohydraulischer kompaktantrieb fuer ventile von turbomaschinen, insbesondere turbinen |
| EP0146841A3 (de) | 1983-12-17 | 1986-11-20 | Consortium für elektrochemische Industrie GmbH | Wasserlösliche Mischether des beta-Cyclodextrins und ein Verfahren zu ihrer Herstellung |
| EP0147685B1 (de) | 1983-12-17 | 1989-04-26 | Hoechst Aktiengesellschaft | Ether des beta-Cyclodextrins und ein Verfahren zu ihrer Herstellung |
| DE3346123A1 (de) | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| MC1710A1 (fr) * | 1984-11-26 | 1986-09-22 | Ciba Geigy Ag | Composes azotes de derives oxo |
| MC1711A1 (fr) | 1984-11-26 | 1986-09-22 | Ciba Geigy Ag | Compose alkylidene-dioxy |
| US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| WO1994004145A1 (en) | 1992-08-21 | 1994-03-03 | Dana Farber Cancer Institute | Treatment of human viral infections |
| WO1996011005A2 (en) | 1994-10-06 | 1996-04-18 | Atlas Leon T | Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases |
| US5763625A (en) | 1995-04-25 | 1998-06-09 | Wisconsin Alumni Research Foundation | Synthesis and use of β-lapachone analogs |
| WO1997007797A1 (en) * | 1995-08-25 | 1997-03-06 | Dana-Farber Cancer Institute | Treatment of human prostate disease with beta-lapachone derivatives |
| US6245807B1 (en) | 1995-08-24 | 2001-06-12 | Dana-Farber Cancer Institute | Treatment of human prostate disease |
| AU6901296A (en) * | 1995-08-24 | 1997-03-19 | Dana-Farber Cancer Institute | Beta-lapachone derivatives as antitumor agents |
| US5883270A (en) | 1996-02-20 | 1999-03-16 | Wisconsin Alumni Research Foundation | 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth |
| US5824700A (en) | 1996-02-20 | 1998-10-20 | Wisconsin Alumni Research Foundation | Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth |
| US6664288B1 (en) | 1999-04-14 | 2003-12-16 | Dana Farber Cancer Institute, Inc. | Method and composition for the treatment of cancer |
| ATE407676T1 (de) | 2000-02-28 | 2008-09-15 | Univ British Columbia | Topoisomerasehemmern zur behandlung von chirurgischen verklebungen |
| US6890950B2 (en) | 2002-04-23 | 2005-05-10 | Case Western Reserve University | Lapachone delivery systems, compositions and uses related thereto |
-
2001
- 2001-10-10 US US09/975,776 patent/US6962944B2/en not_active Expired - Fee Related
-
2002
- 2002-07-31 EA EA200400242A patent/EA007075B1/ru not_active IP Right Cessation
- 2002-07-31 KR KR1020047001569A patent/KR100734341B1/ko not_active Expired - Fee Related
- 2002-07-31 WO PCT/US2002/024262 patent/WO2003011224A2/en not_active Ceased
- 2002-07-31 NZ NZ531335A patent/NZ531335A/en unknown
- 2002-07-31 JP JP2003516456A patent/JP2005507861A/ja active Pending
- 2002-07-31 AU AU2002313713A patent/AU2002313713B2/en not_active Ceased
- 2002-07-31 CN CNA028190297A patent/CN1561209A/zh active Pending
- 2002-07-31 IL IL16010802A patent/IL160108A0/xx unknown
- 2002-07-31 CA CA002455567A patent/CA2455567A1/en not_active Abandoned
- 2002-07-31 BR BR0211613-8A patent/BR0211613A/pt not_active IP Right Cessation
- 2002-07-31 EP EP02753423A patent/EP1420777A4/en not_active Withdrawn
- 2002-07-31 MX MXPA04000994A patent/MXPA04000994A/es active IP Right Grant
-
2008
- 2008-07-21 IL IL192937A patent/IL192937A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6828346B2 (en) | Methods for administration of paclitaxel | |
| CN1169525C (zh) | 紫杉烷的药物制剂 | |
| AU724842B2 (en) | Taxane composition and method | |
| CN1192765C (zh) | 紫杉醇制剂 | |
| DE794794T1 (de) | Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika | |
| CN1178655C (zh) | 紫杉醇的与水混溶的药物组合物 | |
| JP2009523770A (ja) | タキサン医薬製剤、固形タキサン組成物、前記固形タキサン組成物の調製方法、前記固形タキサン組成物を可溶化するための組成物および注射可能なタキサン製剤のための構成要素のセット（キット） | |
| JP2014521722A (ja) | カバジタキセル製剤およびその調製方法 | |
| WO2003011224A3 (en) | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same | |
| EP2566474B1 (en) | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same | |
| KR20190062194A (ko) | 방출제어가 가능한 활성산소 민감성 페로센 나노입자를 포함하는 약물 전달 복합체 및 이의 용도 | |
| RU2010110658A (ru) | Композиции для лечения неопластических заболеваний | |
| EP2275092A1 (en) | Taxane pharmaceutical formulation | |
| AU2021284155A1 (en) | Compositions, their uses in therapy and methods thereof | |
| JP2011529930A (ja) | 注射可能タキサン医薬品組成物 | |
| EP2035020B1 (en) | Pharmaceutical composition for injectional, particularly targeted local administration | |
| RU2485956C2 (ru) | Новая композиция для лечения побочных эффектов противораковой терапии | |
| CN101632637B (zh) | 一种多烯紫杉醇脂质制剂及其制备方法 | |
| WO2022152021A1 (zh) | 含有难溶性抗肿瘤活性剂的药物组合物及其制备方法 | |
| Tyagi et al. | Evaluation of pyrrolobenzodiazepine-loaded nanoparticles: a targeted drug delivery approach | |
| CN101884614B (zh) | 脑靶向川芎嗪口服油包油纳米乳的配制 | |
| BR112017011638B1 (pt) | Nanopartículas para encapsular compostos, processo para a produção das mesmas e composição farmacêutica | |
| CN111712231A (zh) | 用于40-o-环状烃酯和相关结构的肠胃外制剂材料和方法 | |
| CN1031037C (zh) | 局部施用的金有机组合物的制备方法 | |
| HK40029332A (en) | Pharmaceutical compositions containing taxane-cyclodextrin complexes, method of making and methods of use |